Gemcitabine triphosphate

Catalog No. :
ACNYCR719
CAS No. :
110988-86-8
Molecular Formula :
C9H14F2N3O13P3
Molecular Weight :
503.14

IUPAC Name:((2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate

Gemcitabine triphosphate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10mg98%$7547.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameGemcitabine triphosphate
IUPAC Name((2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate
Molecular FormulaC9H14F2N3O13P3
Molecular Weight503.14
SMILESO=P(O)(OP(O)(OP(O)(O)=O)=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O
InChI KeyYMOXEIOKAJSRQX-QPPQHZFASA-N
Synonym2',2'-difluorodeoxycytidine 5'-triphosphate;2'-Deoxy-2',2'-difluorocytidine 5'-triphosphate sodium salt;2'-Deoxy-2',2'-difluorocytidine 5'-triphosphate triethylammonium salt - Aqueous solution;Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-2',2'-difluoro-;Gemcitabine-5'-triphosphate triethylammonium salt;Gemcitabine Impurity 32;2'-dFdCTP Sodium Salt;Bempedoic Acid Impurity 51
CAS No.110988-86-8

Synthetic Route by SureRoute

1. ACNYCR719 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACAYOL972 route compound structure diagram
    ACAYOL97210060-13-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNYCR719 route product structure diagram
    ACNYCR719110988-86-8
Inquiry

2. ACNYCR719 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACAYOL972 route compound structure diagram
    ACAYOL97210060-13-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNYCR719 route product structure diagram
    ACNYCR719110988-86-8
Inquiry

Comments (0)